Viewing Study NCT02908750

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:56 PM
Ignite Modification Date: 2026-02-03 @ 9:32 PM
Study NCT ID: NCT02908750
Status: COMPLETED
Last Update Posted: 2022-11-14
First Post: 2016-08-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None oncology View
None cancer View
None non small cell lung cancer View
None anticancer drug View
None lung neoplasms View
None pharmacokinetics View
None AZD9291 View
None osimertinib View
None fexofenadine View
None TAGRISSO™ View
None EGFR genes View